Dipeptidyl peptidase-4 inhibitor

Examples

Drugs belonging to this class are:

• Sitagliptin (FDA approved in 2006, and marketed by Merck & Co. as Januvia)
• Vildagliptin (EU approved in 2007, and marketed in the EU by Novartis as Galvus)
• Saxagliptin (FDA approved in 2009, and marketed as Onglyza)
• Linagliptin (FDA approved in 2011, and marketed as Tradjenta by Eli Lilly and Company and Boehringer Ingelheim)
• Gemigliptin (approved in Korea in 2012, and marketed by LG Life Sciences as Zemiglo, among other names)
• Anagliptin (approved in Japan as Suiny in 2012; marketed by Sanwa Kagaku Kenkyusho Co., Ltd. and Kowa Company, Ltd.)
• Teneligliptin (approved in Japan as Tenelia in 2012)
• Alogliptin (FDA approved in 2013 as Nesina/Vipidia, and marketed by Takeda Pharmaceutical Company)
• Trelagliptin (approved for use in Japan as Zafatek/Wedica in 2015)
• Omarigliptin (MK-3102; approved as Marizev in Japan in 2015, having been developed by Merck & Co. In November 2015, Sheu and colleagues showed that omarigliptin could be used once-weekly and was generally well tolerated throughout the base and extension studies)
• Evogliptin (approved as Suganon/Evodine for use in South Korea)
• Gosogliptin (approved as Saterex for use in Russia)
• Dutogliptin (PHX- 1149; being developed by Phenomix Corporation. In a phase III trial as of April 2010)
• Neogliptin
• Retagliptin (SP-2086; approved in China)
• Denagliptin
• Cofrogliptin (HSK- 7653; compound 2)
• Fotagliptin
• Prusogliptin
• Cetagliptin (CGT 8012)

Berberine, an alkaloid found in plants of the genus Berberis (the "barberry"), inhibits DPP-4, which may at least partly explains the chemical's antihyperglycemic activity.

Adverse effects

In individuals already taking sulphonylureas, use of DPP-4-class medications concurrently increases their risk for low blood sugar events relative to those on sulphonylureas alone.

Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity, and skin reactions.

In late August 2015, the US FDA issued a warning that drugs like sitagliptin, saxagliptin, linagliptin, alogliptin, and other DPP-4 inhibitors could cause joint pain that can be severe and disabling. However, studies assessing risk of rheumatoid arthritis among DPP-4 inhibitor users have been inconclusive. A 2014 review found that the use of saxagliptin and alogliptin increased individuals' risk of developing heart failure, leading the FDA to add warnings to the labels of these drugs in 2016. A 2018 meta-analysis indicated that the use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared to placebo or no treatment. Additionally, a 2018 observational study suggested an elevated risk of developing inflammatory bowel disease, specifically ulcerative colitis, which peaked after three to four years of use and decreased after more than four years. Finally, a 2020 Cochrane systematic review found insufficient evidence to suggest that metformin monotherapy reduced all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or end-stage renal disease when compared to DPP-4 inhibitors for the treatment of type 2 diabetes.

Cancer

In response to a report of precancerous changes in the pancreases of rats and organ donors treated with the DPP-4 inhibitor sitagliptin, the US FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-4 inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicine, the agencies stated that they had not yet reached a final conclusion regarding a possible causative relationship. A 2014 meta-analysis found no evidence for increased pancreatic cancer risk in people treated with DPP-4 inhibitors, but owing to the modest amount of data available, the authors were unable to completely exclude possibly increased risk.

Combination drugs

Some DPP-4 inhibitor drugs have received approval from the FDA to be used with metformin concomitantly with additive effect to increase the level of glucagon-like peptide 1 (GLP-1) which also decreases hepatic glucose production.

References

References

1. (October 17, 2006). "FDA Approves New Treatment for Diabetes". U.S. Food and Drug Administration.
2. (June 2005). "Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?". Regulatory Peptides.
3. (April 2003). "Glucagon-like peptide 1 improved glycemic control in type 1 diabetes". BMC Endocrine Disorders.
4. (June 1995). "Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM". Diabetes.
5. (April 2018). "Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis". JAMA.
6. {{UTGlucagon. sitagliptin
7. {{UTGlucagon. vildagliptin
8. (2011-05-02). "FDA approves new treatment for Type 2 diabetes". Fda.gov.
9. "LG Life Science". Lgls.com.
10. "New Drugs Approved in FY 2012".
11. (2012). "Teneligliptin (Antidiabetic). To Market, To Market". Annual Reports in Medicinal Chemistry.
12. (28 September 2015). "Merck MARIZEV Once-Weekly DPP-4 Inhibitor For Type2 Diabetes Approved In Japan". NASDAQ.
13. (November 2015). "Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes". Diabetes Care.
14. (October 2, 2015). "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com.
15. "SatRx LLC Announces First Registration in Russia of SatRx (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes". SatRx LLC.
16. (2010-04-20). "Forest Splits With Phenomix".
17. (February 2022). "Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)". Pharmaceuticals.
18. (October 2009). "Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine". Journal of Enzyme Inhibition and Medicinal Chemistry.
19. (May 2016). "Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis". BMJ.
20. (2015-08-28). "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain".
21. (February 2018). "DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control Study". Diabetes Therapy.
22. (April 2016). "Diabetes Meds Containing Saxagliptin and Alogliptin Linked to Increased HF". Pharmacy Practice News.
23. (April 2018). "Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis". JAMA.
24. (March 2018). "Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study". BMJ.
25. (June 2020). "Metformin monotherapy for adults with type 2 diabetes mellitus". The Cochrane Database of Systematic Reviews.
26. (July 2009). "Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin". Diabetes.
27. (July 2013). "Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors". Diabetes.
28. (February 2014). "Pancreatic safety of incretin-based drugs--FDA and EMA assessment". The New England Journal of Medicine.
29. (January 2014). "Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials". Diabetes, Obesity & Metabolism.